Cita APA

Nash, P., Coates, L., Kivitz, A., Mease, P., Gladman, D., Covarrubias-Cobos, J., . . . Kanik, K. (2018). Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: Data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study. Wiley.

Citación estilo Chicago

Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-term Extension Study. Wiley, 2018.

Cita MLA

Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-term Extension Study. Wiley, 2018.